Abstract
Aggressive immunity characterized by the motion of cytotoxic T lymphocytes (CTLs), T helper (Th) 1 cells, and natural killer (NK) cells is the first line of defense against intracellular microorganism invasion and tumor formation. In patients with infectious diseases and tumors, aggressive immunity is often attenuated by immune suppressive effects provided by regulatory T (Treg) cells including CD4+ CD25+ forkhead-box (fox) p3+ T cells, T regulatory (Tr) 1, Th3, and a subpopulation of γδ-type of T cell receptor-expressing T (γδ T) cells. It has been demonstrated that Treg cells down-regulate aggressive immunity by direct cell interactions and suppressive cytokines (e.g., interleukin (IL)-10, transforming growth factor (TGF)-β). Today, instead of synthesizing chemical agents with serious side effects, protein agents, catalytic oligonucleotides, and natural medicines involved in the elimination of Treg cell-mediated suppressive responses for the restoration of aggressive immunity are expected to be alternatives as a mild clinical remedy against microorganism invasion and tumors.
Keywords: Anti-infective immunity, anti-tumor immunity, aptamer, fludarabine, immune suppression, natural medicine, regulatory T cell, mild medicine
Current Medicinal Chemistry
Title: Anti-Infective and Anti-Tumor Agents Based on the Depletion of Immune Suppressive Effects
Volume: 15 Issue: 10
Author(s): Naohiro Seo, Hiromichi Yamashiro and Toshimasa Tadaki
Affiliation:
Keywords: Anti-infective immunity, anti-tumor immunity, aptamer, fludarabine, immune suppression, natural medicine, regulatory T cell, mild medicine
Abstract: Aggressive immunity characterized by the motion of cytotoxic T lymphocytes (CTLs), T helper (Th) 1 cells, and natural killer (NK) cells is the first line of defense against intracellular microorganism invasion and tumor formation. In patients with infectious diseases and tumors, aggressive immunity is often attenuated by immune suppressive effects provided by regulatory T (Treg) cells including CD4+ CD25+ forkhead-box (fox) p3+ T cells, T regulatory (Tr) 1, Th3, and a subpopulation of γδ-type of T cell receptor-expressing T (γδ T) cells. It has been demonstrated that Treg cells down-regulate aggressive immunity by direct cell interactions and suppressive cytokines (e.g., interleukin (IL)-10, transforming growth factor (TGF)-β). Today, instead of synthesizing chemical agents with serious side effects, protein agents, catalytic oligonucleotides, and natural medicines involved in the elimination of Treg cell-mediated suppressive responses for the restoration of aggressive immunity are expected to be alternatives as a mild clinical remedy against microorganism invasion and tumors.
Export Options
About this article
Cite this article as:
Seo Naohiro, Yamashiro Hiromichi and Tadaki Toshimasa, Anti-Infective and Anti-Tumor Agents Based on the Depletion of Immune Suppressive Effects, Current Medicinal Chemistry 2008; 15 (10) . https://dx.doi.org/10.2174/092986708784049603
DOI https://dx.doi.org/10.2174/092986708784049603 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cigarette Smoking, Metabolic Activation and Carcinogenesis
Current Drug Metabolism Interplay between RNA Methylation Eraser <i>FTO</i> and Writer <i>METTL3</i> in Renal Clear Cell Carcinoma Patient Survival
Recent Patents on Anti-Cancer Drug Discovery Herb-Drug Interactions and Mechanistic and Clinical Considerations
Current Drug Metabolism Cyclin-Dependent Kinase-2 as a Target for Cancer Therapy: Progress in the Development of CDK2 Inhibitors as Anti-Cancer Agents
Current Medicinal Chemistry Liquid Chromatographic Analysis of Methotrexate and Minocycline-relevance to the Determination in Plasma/Nanoparticulate Formulations
Current Chromatography Bupropion in the Depression-Related Sexual Dysfunction: A Systematic Review
CNS & Neurological Disorders - Drug Targets Aspirin as a Chemoprevention Agent for Colorectal Cancer
Current Drug Metabolism Carbon Nano Tubes: Novel Drug Delivery System in Amelioration of Alzheimer’s Disease
Combinatorial Chemistry & High Throughput Screening Gender as a Regulator of Atherosclerosis in Murine Models
Current Drug Targets Pentoxifylline Use in Dermatology
Inflammation & Allergy - Drug Targets (Discontinued) The Implications of Sortilin/Vps10p Domain Receptors in Neurological and Human Diseases
CNS & Neurological Disorders - Drug Targets Do Folate, Vitamins B<sub>6</sub> and B<sub>12</sub> Play a Role in the Pathogenesis of Migraine? The Role of Pharmacoepigenomics
CNS & Neurological Disorders - Drug Targets Indolo[2,3-a]quinolizidines and Derivatives: Bioactivity and Asymmetric Synthesis
Current Pharmaceutical Design Promising Chemoprevention of Colonic Aberrant Crypt Foci by <i>Portunus segnis</i> Muscle and Shell Extracts in Azoxymethane-Induced Colorectal Cancer in Rats
Anti-Cancer Agents in Medicinal Chemistry Biomarkers in Molecularly Targeted Therapy for Cancer
Recent Patents on Biomarkers Drug Discovery and the Impact of the Safe Harbor Provision of the Hatch-Waxman Act
Current Topics in Medicinal Chemistry The IFN-λ Family (IL-28/29)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Adenosine Receptors as Novel Targets for the Treatment of Various Cancers
Current Pharmaceutical Design Trifluoroibuprofen Inhibits α-Methylacyl Coenzyme A Racemase (AMACR/P504S), Reduces Cancer Cell Proliferation and Inhibits in vivo Tumor Growth in Aggressive Prostate Cancer Models
Anti-Cancer Agents in Medicinal Chemistry MicroRNA Therapeutics: the Next Magic Bullet?
Mini-Reviews in Medicinal Chemistry